Vibes, FOMO, and the Funding Gap: Why Investment Doesn't Always Follow the Best Science
Researchers who spent a decade building rigorous evidence find themselves competing with founders who spent a weekend building a narrative. Understanding why the investment room works this way — and how to beat it at its own game — is no longer optional.
In 2021, a synthetic biology startup founded by two researchers with strong publication records and a validated platform for biosensor development entered a competitive pitch event alongside eleven other deep-tech ventures. They finished ninth. The company that won had a less developed technology, no peer-reviewed validation, and a founding team with no domain publications. What it had was a founder who had previously exited a consumer app, a deck built by a professional design studio, and a narrative that opened with a striking statistic about global food waste and closed with a vision of planetary-scale impact. The judges were not unintelligent. They were operating, as investors routinely do, on the information available to them in forty minutes — and in forty minutes, story travels faster than evidence.
This is not an aberration. It is a structural feature of early-stage investment that the research community has been slow to reckon with honestly. The venture capital system — and the deep-tech funding landscape that has grown around it — does not make decisions the way science does. It cannot. And understanding why reveals something important: the problem is not that investors are irrational. The problem is that researchers are arriving without the tools to make rationality easy.
The psychology of investment has been studied with increasing rigour since the behavioural economics revolution of the 1980s and 1990s, and what that research consistently shows is uncomfortable for anyone who believes capital allocation is a primarily analytical exercise. Early-stage investment decisions are made under conditions of radical uncertainty — the technology is unproven at scale, the market is contested, the team is untested in this specific context — and under those conditions, human decision-making reliably shifts toward heuristics, pattern recognition, and affect. Investors back founders who remind them of founders who previously succeeded. They respond to narratives that trigger loss aversion — the fear of missing the next platform technology — more than to evidence that triggers deliberate analysis. They make faster, more confident decisions when they feel a strong emotional response to a pitch, and they rationalise those decisions analytically afterward.
The term FOMO — fear of missing out — entered mainstream investment vocabulary in the early 2010s, coinciding with the first wave of hyper-valued consumer technology companies whose returns had made early investors spectacularly wealthy. It described a real and well-documented phenomenon: investors who had passed on companies that later became enormously valuable became systematically more inclined to fund based on excitement and momentum rather than detailed diligence. The rational response to having missed Uber, the logic ran, was to move faster and trust gut instinct more. The culture that resulted privileged founders who could generate excitement quickly — and disadvantaged those whose most important assets required time and expertise to evaluate.
A 2019 study by Harvard Business School researchers analysed 2,000 early-stage investment decisions and found that over 60% of the variance in funding outcomes was explained by factors unrelated to the technology itself — including founder presentation style, narrative coherence, and the emotional response the pitch generated in evaluators. A separate study in the Academy of Management Journal found that deep-tech ventures were systematically disadvantaged in standard VC pitch formats compared to consumer or software ventures, because their core value proposition required domain expertise to evaluate and could not be communicated through analogy to existing successful companies. The researchers termed this the "legibility gap": not a quality gap, but a communication gap that the investment process had no mechanism to correct.
For researchers trained in the careful accumulation and presentation of evidence, this landscape is genuinely disorienting. The norms they have internalised — qualify claims appropriately, acknowledge limitations, let the data speak — are actively counterproductive in an environment where the investor's primary question is not "is this true?" but "can I get excited about this, and will other investors share my excitement?" The researcher who presents a balanced assessment of their technology's current limitations and development requirements is, in the logic of the investment room, communicating doubt. The founder who presents a bold vision of market transformation with compressed technical detail is communicating conviction. Conviction, in early-stage investment, is a currency. Evidence is not, on its own, enough.
"I do not enjoy saying this, but the honest answer is that we fund stories first and diligence the science afterward. If the story doesn't make us lean forward, the science never gets its day. That is not ideal. It is the reality of how we operate in a world with forty pitches a week."
— Partner at a European deep-tech venture fund, speaking on backgroundThe consequences for science-based ventures are both specific and compounding. In the short term, technologies with genuine transformative potential lose funding rounds to ventures with superior narrative packaging and weaker underlying science — a misallocation that is invisible in individual cases and significant in aggregate. Capital flows toward what can be communicated in forty minutes rather than toward what the evidence supports, and the portfolio of funded deep-tech ventures ends up shaped more by the rhetorical capacities of founders than by the quality of the underlying research.
In the medium term, researchers who experience repeated rejection without understanding the diagnosis draw the wrong conclusion — that their technology is insufficiently compelling rather than insufficiently framed — and either abandon commercialisation or, more damagingly, begin to believe that the investment community is simply hostile to serious science. Some of that hostility is real. Much of what feels like hostility is, in fact, a communication problem that has a solution.
"The investor who passed on us was not wrong to want a compelling story. We were wrong to think our data was the story. The data was the proof. The story was something we had never built."
The longer-term consequence is a quiet distortion of the innovation pipeline. When vibes and FOMO systematically outperform rigour in the funding room, the researchers who adapt — who learn to lead with narrative, to deploy market statistics for emotional effect, to speak the language of disruption before the language of mechanism — succeed. Those who do not, do not. The system is not selecting for the best science. It is selecting for the best-communicated science, which is a different thing — and the gap between those two populations represents an enormous volume of unrealised scientific value.
The answer is not to bemoan the irrationality of investment culture, nor to wait for a funding landscape that evaluates deep tech with the patience and domain expertise it deserves. Both of those responses are understandable, and both are strategically useless. The answer is to understand the game being played and arrive equipped to play it — without sacrificing the integrity of the underlying science.
What makes a data-driven pitch stronger than any vibe is not the absence of narrative. It is a narrative so grounded in verified market intelligence that it cannot be dismissed as enthusiasm. When a researcher opens with a precise, externally validated market sizing — not a number extracted from a decade-old industry report, but a current, sourced, credible figure — and builds from it to a specific, defensible claim about where their technology fits and why the timing is right, they are doing something the vibe-driven founder cannot do: they are making excitement and rigour the same thing.
This is what a well-constructed market intelligence document accomplishes — a concise, professionally prepared analysis that translates the technology's commercial context into the language investors use to make decisions: the problem size, the current solutions and their failure modes, the competitive white space, the evidence of market readiness. Not a scientific abstract repackaged. A genuine market intelligence product, built by people who understand both the science and the investment room, and designed to do one specific job: give the researcher standing in front of a panel the kind of hard, current, compelling data that turns a vibe into a conviction.
Investors do not fund vibes because they are shallow. They fund vibes because, too often, it is the most substantive thing on offer. Give them something more substantive — presented with the clarity and confidence that comes from knowing your market as well as you know your molecule — and the vibe becomes irrelevant. The data becomes the story. And that is a story that holds up in due diligence, in board meetings, and in the long arc of building something that the research deserved to become.